PMID- 32318939
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 1573-2630 (Electronic)
IS  - 0165-5701 (Linking)
VI  - 40
IP  - 5
DP  - 2020 May
TI  - Outcome and risk of ocular complications of managing children with chronic 
      anterior uveitis with topical rimexolone 1.
PG  - 1061-1068
LID - 10.1007/s10792-020-01358-9 [doi]
AB  - PURPOSE: To investigate the efficacy and safety of 1% rimexolone ophthalmic 
      suspension in children with chronic anterior uveitis under real-life conditions 
      in a tertiary center. METHODS: This is a retrospective longitudinal study. 
      Medical records were analyzed at baseline, 1, 3, 6 and 12 months before and after 
      switching to rimexolone for best-corrected visual acuity (BCVA), oral steroid 
      use, number of flares, IOP and anti-glaucoma management. RESULTS: Twenty-four 
      patients (41 eyes) diagnosed with either anterior uveitis (n = 25, 60.0%) or 
      panuveitis (n = 16, 40%) were enrolled. The mean age was 10.5 years (4-16 years). 
      The number of patients requiring oral prednisolone reduced from 8 patients 
      (32.0%) at baseline to 3 patients (20.0%) at 12 months (P < 0.001). Following 
      baseline, the median number of uveitis flares reduced from 2.0 (inter-quartile 
      range (IQR) 1.0-2.75) to 1.0 (IQR 0.0-1.0) compared to the 12 months before 
      baseline (P < 0.001). The mean IOP reduced from baseline (22.0 +/- 7.3 mmHg) to 
      1 month (18.8 +/- 8.7 mmHg, P = 0.01) and remained stable up to 12 months 
      (15.9 +/- 5.0 mmHg, P < 0.001). Average BCVA, dose of oral prednisolone and 
      anti-glaucoma treatments did not change compared to the baseline. The development 
      for IOP >/= 30 mmHg was associated with a known corticosteroid response [odds ratio 
      (OR) 6.8, P = 0.003] and a dose > 7.5 mg/day oral prednisolone (OR 4.4, 
      P = 0.033). CONCLUSIONS: Rimexolone 1% ophthalmic suspension is an effective and 
      safe topical steroid for pediatric anterior uveitis.
FAU - Chen, Yi-Hsing
AU  - Chen YH
AD  - Institute of Ophthalmology, University College of London, London, UK.
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
AD  - Moorfields Eye Hospital, London, UK.
FAU - Gepstein, Raz
AU  - Gepstein R
AD  - Moorfields Eye Hospital, London, UK.
FAU - Sharief, Lazha
AU  - Sharief L
AD  - Institute of Ophthalmology, University College of London, London, UK.
AD  - Moorfields Eye Hospital, London, UK.
FAU - Tseng, Hsiao-Jung
AU  - Tseng HJ
AD  - Biostatistical Center for Clinical Research, Chang Gung Memorial Hospital, 
      Taoyuan, Taiwan.
FAU - Wei, Ruoxin
AU  - Wei R
AD  - Moorfields Eye Hospital, London, UK.
FAU - Zhang, Xiaozhe
AU  - Zhang X
AD  - Institute of Ophthalmology, University College of London, London, UK.
FAU - Lightman, Sue
AU  - Lightman S
AD  - Institute of Ophthalmology, University College of London, London, UK.
AD  - Moorfields Eye Hospital, London, UK.
FAU - Tomkins-Netzer, Oren
AU  - Tomkins-Netzer O
AUID- ORCID: 0000-0002-1015-1641
AD  - Institute of Ophthalmology, University College of London, London, UK. 
      oren.tomkins@gmail.com.
AD  - Moorfields Eye Hospital, London, UK. oren.tomkins@gmail.com.
AD  - Ophthalmology Department, Lady Davis Carmel Medical Center, Technion-Israel 
      Institute of Technology, Haifa, Israel. oren.tomkins@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200421
PL  - Netherlands
TA  - Int Ophthalmol
JT  - International ophthalmology
JID - 7904294
RN  - 0 (Glucocorticoids)
RN  - 0 (Ophthalmic Solutions)
RN  - 0 (Pregnadienes)
RN  - O7M2E4264D (rimexolone)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Chronic Disease
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Glaucoma/*etiology/physiopathology
MH  - Glucocorticoids/administration & dosage
MH  - Humans
MH  - Intraocular Pressure/drug effects
MH  - Male
MH  - Ophthalmic Solutions/administration & dosage
MH  - Pregnadienes/*administration & dosage
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Uveitis, Anterior/complications/diagnosis/*drug therapy
MH  - *Visual Acuity
OTO - NOTNLM
OT  - Intraocular pressure
OT  - Pediatric
OT  - Rimexolone
OT  - Uveitis
EDAT- 2020/04/23 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/04/23 06:00
PHST- 2019/01/08 00:00 [received]
PHST- 2019/11/08 00:00 [accepted]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.1007/s10792-020-01358-9 [pii]
AID - 10.1007/s10792-020-01358-9 [doi]
PST - ppublish
SO  - Int Ophthalmol. 2020 May;40(5):1061-1068. doi: 10.1007/s10792-020-01358-9. Epub 
      2020 Apr 21.